Verséa Biologics is a division of Verséa Holdings, Inc., a diversified healthcare company committed to transforming scientific discoveries into applicable solutions that are critical to improving patients’ lives.

The Verséa Biologics Team, headed by Dr. Sunil J. Panchal, M.D., Ph.D., Chief Scientific Officer, is focused on using the latest cutting-edge scientific advancements in regenerative medicine to provide novel treatment solutions for a broad range of musculoskeletal and regenerative conditions that support the body’s natural ability to heal.

An impressive Product Portfolio contains the latest innovative products that are fully compliant with the new FDA HCT regulations and use the progenerative power of amnion to help solve wound care, ocular care, and pain management problems. The portfolio provides reimbursable healthcare options (Medicare & BCBS).

The portfolio is a result of Verséa’s partnership with Celularity, a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies targeting indications across both infectious and degenerative diseases.

Verséa is an Exclusive Distributor for Celularity’s Regenerative Medicine Portfolio in the UAE, and an Exclusive Master Distributor for Biovance®* 3L Ocular in the USA.

*Biovance® is a registered trademark of Celularity Inc.